NCT04714697View on ClinicalTrials.gov

Cabozantinib as Subsequent Therapy to an Immune Checkpoint Based Therapy in Renal Cell Carcinoma

PHASE2UnknownINTERVENTIONAL
Enrollment

201

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

February 28, 2023

Study Completion Date

February 28, 2025

Conditions
Renal Cell Cancer
Interventions
DRUG

Cabometyx

Cabometyx 60mg once daily, oral , up to Progression disease

Trial Locations (1)

138-736

Asan Medical Center, Seoul

Sponsors

Collaborators (1)

Ipsen
All Listed Sponsors
collaborator

Ipsen

INDUSTRY

lead

Asan Medical Center

OTHER